Concordance of Mycobacterium tuberculosis fluoroquinolone resistance testing: implications for treatment

M R Farhat; C D Mitnick; M F Franke; D Kaur; A Sloutsky; M Murray; K R Jacobson

doi:10.5588/ijtld.14.0814

Concordance of Mycobacterium tuberculosis fluoroquinolone resistance testing: implications for treatment

Int J Tuberc Lung Dis. 2015 Mar;19(3):339-41. doi: 10.5588/ijtld.14.0814.

Authors

M R Farhat¹, C D Mitnick², M F Franke³, D Kaur⁴, A Sloutsky⁴, M Murray⁵, K R Jacobson⁶

Affiliations

¹ Division of Pulmonary and Critical Care Medicine, Massachusetts General Hospital, Boston, USA; Department of Global Health and Social Medicine, Harvard Medical School, Boston, USA.
² Department of Global Health and Social Medicine, Harvard Medical School, Boston, USA; Department of Global Health Equity, Brigham and Women's Hospital, Boston, USA.
³ Department of Global Health and Social Medicine, Harvard Medical School, Boston, USA.
⁴ University of Massachusetts Medical School, Massachusetts Supranational TB Reference Laboratory, Boston, USA.
⁵ Department of Global Health and Social Medicine, Harvard Medical School, Boston, USA; Department of Epidemiology, Harvard School of Public Health, Boston, USA.
⁶ Section of Infectious Diseases, Boston University School of Medicine, Boston, Massachusetts, USA; Department of Science & Technology, National Research Foundation Centre of Excellence for Biomedical TB Research/Medical Research Council Centre for Molecular and Cellular Biology, Division of Molecular Biology and Human Genetics, Faculty of Medicine and Health Sciences, Stellenbosch University, Tygerberg, South Africa.

Abstract

Fluoroquinolone (FQ) drug susceptibility testing (DST) is an important step in the design of effective treatment regimens for multidrug-resistant tuberculosis. Here we compare ciprofloxacin, ofloxacin and moxifloxacin (MFX) resistance results from 226 multidrug-resistant samples. The low level of concordance observed suggests that DST should be performed for the specific FQ planned for clinical use. The results also support the new World Health Organization recommendation for testing MFX at a critical concentration of 2.0 μg/ml.

Publication types

Comparative Study
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't

MeSH terms

Ciprofloxacin / pharmacology
Dose-Response Relationship, Drug
Fluoroquinolones / pharmacology*
Humans
Microbial Sensitivity Tests
Moxifloxacin
Mycobacterium tuberculosis / drug effects*
Ofloxacin / pharmacology
Treatment Outcome
Tuberculosis, Multidrug-Resistant / drug therapy*

Substances

Fluoroquinolones
Ciprofloxacin
Ofloxacin
Moxifloxacin

Abstract

Publication types

MeSH terms

Substances

Grants and funding